Eli Lilly has established itself as a powerhouse in the pharmaceutical industry, with a particular focus on diabetes care, oncology, immunology, and neuroscience. The company's recent success has ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity ...

but taking into account the huge need there would probably continue to be supply constraints until we had an oral medicine with an injectable-like efficacy,” President of Lilly Diabetes and ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies – but still said sales rose around a third over the prior year.

The results are an uncomfortable echo of late October 2024, when Mounjaro and Zepbound missed by similar margins. Those ...

On Tuesday, Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus ...

Pharma major Lupin has acquired Huminsulin brand in India from Eli Lilly, in an effort to enhance its diabetes portfolio, the company said in an exchange filing on December 30. Lupin had been ...

Shares of Eli Lilly & Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the ...

Photo Credit: vitapix Drugmaker Lupin Ltd has acquired Huminsulin in India from Eli Lilly and Company, for an undisclosed amount. The move will strengthen Lupin’s diabetes footprint in the country.